Compare WIX & KRYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WIX | KRYS |
|---|---|---|
| Founded | 2006 | 2015 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.6B | 6.3B |
| IPO Year | 2013 | 2017 |
| Metric | WIX | KRYS |
|---|---|---|
| Price | $97.34 | $248.54 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 21 | 9 |
| Target Price | $183.62 | ★ $226.56 |
| AVG Volume (30 Days) | ★ 1.1M | 285.6K |
| Earning Date | 02-18-2026 | 02-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 47.59 | ★ 275.72 |
| EPS | 2.36 | ★ 6.66 |
| Revenue | ★ $1,929,230,000.00 | $373,164,000.00 |
| Revenue This Year | $14.56 | $36.14 |
| Revenue Next Year | $14.23 | $41.80 |
| P/E Ratio | $42.43 | ★ $36.98 |
| Revenue Growth | 13.22 | ★ 54.51 |
| 52 Week Low | $92.23 | $122.80 |
| 52 Week High | $247.11 | $265.92 |
| Indicator | WIX | KRYS |
|---|---|---|
| Relative Strength Index (RSI) | 33.25 | 62.15 |
| Support Level | $99.55 | $245.68 |
| Resistance Level | $102.88 | $257.95 |
| Average True Range (ATR) | 3.20 | 7.95 |
| MACD | 0.15 | -1.56 |
| Stochastic Oscillator | 13.76 | 63.04 |
Wix.com is a software-as-a-service content management system platform that allows users to create, customize, and manage websites for themselves, or for clients. Wix is best known for its Wix Editor service for self-creators, but in recent years has invested heavily and introduced its Wix Studio offering for partners, who are agencies and developers. Wix also offers a range of business solutions such as payment services and marketing products.
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.